171 related articles for article (PubMed ID: 34405834)
1. Remission of Severe Eyelid Dermatitis With a Topical Janus Kinase Inhibitor.
Peterson D; King B
Dermatitis; 2021 Oct; 32(1S):e98-e99. PubMed ID: 34405834
[No Abstract] [Full Text] [Related]
2. Topical tacrolimus treatment of atopic eyelid disease.
Rikkers SM; Holland GN; Drayton GE; Michel FK; Torres MF; Takahashi S
Am J Ophthalmol; 2003 Mar; 135(3):297-302. PubMed ID: 12614745
[TBL] [Abstract][Full Text] [Related]
3. Treatment of atopic eyelid disease using topical tacrolimus following corticosteroid discontinuation in a patient with open-angle glaucoma.
Kymionis GD; Tsilimbaris MK; Iliaki OE; Christodoulakis E; Siganos CS; Pallikaris IG
Cornea; 2004 Nov; 23(8):828-30. PubMed ID: 15502487
[TBL] [Abstract][Full Text] [Related]
4. Phase 1 studies to assess the safety, tolerability and pharmacokinetics of JTE-052 (a novel Janus kinase inhibitor) ointment in Japanese healthy volunteers and patients with atopic dermatitis.
Nakagawa H; Nemoto O; Yamada H; Nagata T; Ninomiya N
J Dermatol; 2018 Jun; 45(6):701-709. PubMed ID: 29665062
[TBL] [Abstract][Full Text] [Related]
5. Delgocitinib ointment, a topical Janus kinase inhibitor, in adult patients with moderate to severe atopic dermatitis: A phase 3, randomized, double-blind, vehicle-controlled study and an open-label, long-term extension study.
Nakagawa H; Nemoto O; Igarashi A; Saeki H; Kaino H; Nagata T
J Am Acad Dermatol; 2020 Apr; 82(4):823-831. PubMed ID: 32029304
[TBL] [Abstract][Full Text] [Related]
6. Safety and efficacy of upadacitinib in combination with topical corticosteroids in adolescents and adults with moderate-to-severe atopic dermatitis (AD Up): results from a randomised, double-blind, placebo-controlled, phase 3 trial.
Reich K; Teixeira HD; de Bruin-Weller M; Bieber T; Soong W; Kabashima K; Werfel T; Zeng J; Huang X; Hu X; Hendrickson BA; Ladizinski B; Chu AD; Silverberg JI
Lancet; 2021 Jun; 397(10290):2169-2181. PubMed ID: 34023009
[TBL] [Abstract][Full Text] [Related]
7. Janus kinase inhibitor delgocitinib suppresses pruritus and nerve elongation in an atopic dermatitis murine model.
Yamamoto Y; Otsuka A; Nakashima C; Ishida Y; Honda T; Egawa G; Amano W; Usui K; Hamada Y; Wada M; Tanimoto A; Konishi N; Hayashi M; Matsushita M; Kabashima K
J Dermatol Sci; 2020 Feb; 97(2):161-164. PubMed ID: 31924380
[No Abstract] [Full Text] [Related]
8. Efficacy of tofacitinib in Kimura's disease in a patient with concomitant atopic dermatitis.
Sun Q; Fu B; Li S; Fang H; Qiao J
Clin Exp Dermatol; 2021 Oct; 46(7):1336-1338. PubMed ID: 33837590
[No Abstract] [Full Text] [Related]
9. A case of widespread molluscum contagiosum caused by baricitinib, a Janus kinase inhibitor.
Wong GN; Lee S; Foley P
Australas J Dermatol; 2019 Nov; 60(4):e334-e335. PubMed ID: 31012089
[No Abstract] [Full Text] [Related]
10. Refractory cutaneous lichen amyloidosis coexisting with atopic dermatitis responds to the Janus Kinase inhibitor baricitinib.
Xia D; Xiao Y; Li M; Li W
Dermatol Ther; 2022 Sep; 35(9):e15724. PubMed ID: 35855568
[No Abstract] [Full Text] [Related]
11. Janus kinase inhibitors for atopic dermatitis: a promising treatment modality.
Cartron AM; Nguyen TH; Roh YS; Kwatra MM; Kwatra SG
Clin Exp Dermatol; 2021 Jul; 46(5):820-824. PubMed ID: 33484582
[TBL] [Abstract][Full Text] [Related]
12. Long-term safety and efficacy of delgocitinib ointment, a topical Janus kinase inhibitor, in adult patients with atopic dermatitis.
Nakagawa H; Nemoto O; Igarashi A; Saeki H; Murata R; Kaino H; Nagata T
J Dermatol; 2020 Feb; 47(2):114-120. PubMed ID: 31820485
[TBL] [Abstract][Full Text] [Related]
13. JAK/STAT inhibitors for the treatment of atopic dermatitis.
Rodrigues MA; Torres T
J Dermatolog Treat; 2020 Feb; 31(1):33-40. PubMed ID: 30703333
[No Abstract] [Full Text] [Related]
14. The Rate of Infections With Janus Kinase Inhibitor Treatment for Atopic Dermatitis: A Systematic Review and Meta-Analysis.
Tarafdar N; Sachdeva M; Dubale NM; Smythe C; Lytvyn Y; Maliyar K; Georgakopoulos JR; Mufti A; Yeung J
J Cutan Med Surg; 2024; 28(1):83-85. PubMed ID: 37968918
[No Abstract] [Full Text] [Related]
15. Innovation in the treatment of atopic dermatitis: Emerging topical and oral Janus kinase inhibitors.
Nakashima C; Yanagihara S; Otsuka A
Allergol Int; 2022 Jan; 71(1):40-46. PubMed ID: 34815171
[TBL] [Abstract][Full Text] [Related]
16. Quantitative evaluation of eyelid elasticity using the cutometer SEM575 and its clinical application in assessing the efficacy of tacrolimus ointment treatment in eyelid atopic dermatitis.
Kawakita T; Takano Y; Asano-Kato N; Tanaka M; Dogru M; Goto E; Tsubota K; Takahashi S; Fukagawa K; Fujishima H
Cornea; 2004 Jul; 23(5):468-71. PubMed ID: 15220731
[TBL] [Abstract][Full Text] [Related]
17. The underrepresentation of older adults in clinical trials of Janus kinase inhibitors in the treatment of atopic dermatitis.
Sreekantaswamy SA; Tully J; Edelman LS; Supiano MA; Butler D
J Am Acad Dermatol; 2022 Nov; 87(5):1174-1176. PubMed ID: 35245563
[No Abstract] [Full Text] [Related]
18. Janus Kinase Inhibitors in the Treatment of Atopic Dermatitis: Military Considerations.
Nolan CF
Cutis; 2022 Dec; 110(6):316-320. PubMed ID: 36735987
[TBL] [Abstract][Full Text] [Related]
19. Janus Kinase Inhibitors in Dermatology: Part 2: Applications in Psoriasis, Atopic Dermatitis, and Other Dermatoses.
Garcia-Melendo C; Cubiró X; Puig L
Actas Dermosifiliogr (Engl Ed); 2021; 112(7):586-600. PubMed ID: 34030992
[TBL] [Abstract][Full Text] [Related]
20. Emerging therapies for atopic dermatitis: JAK inhibitors.
Cotter DG; Schairer D; Eichenfield L
J Am Acad Dermatol; 2018 Mar; 78(3 Suppl 1):S53-S62. PubMed ID: 29248518
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
